Neuropace, Inc. (NPCE) fundamentals score
Neuropace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 5.2 out of 10, Mixed fundamentals
- Growth: 6.3/10
- Profitability: 4.3/10
- Financial health: 3.3/10
- Earnings quality: 7.8/10
- Valuation: 5.0/10
Scores are calculated from Neuropace, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10